Formac Signs Feasibility Agreement with major German Pharma Company
Formac Pharmaceuticals NV, a drug delivery company focused on developing silica-based formulations for poorly water-soluble drugs, and its strategic partner W. R. Grace & Co., a leading global manufacturer of silica, today announced that they have signed a feasibility study agreement with a major German pharmaceutical company. Within the framework of this agreement, the utility of Formac and Grace's mesoporous silica technology (SilSol®) will be evaluated for several poorly water-soluble drug candidates.
"This agreement follows the recent successes of Formac and Grace in developing and positioning the SilSol® technology. We have reached key technological milestones in terms of innovative silica design and synthesis, loading of our proprietary silicas with active ingredients and the processing of our loaded silicas into finished drug products. These developments enable clear value creation for our customers and we are very proud to have the opportunity to collaborate with such a renowned company" said Formac CEO, Laurent Schueller.